Cellbion receives Phase 3 IND approval for prostate cancer t∙∙∙

Cellbion pursue dual-track RPT drug strategy with 'condition∙∙∙

Cellbion Selected for MOTIE's National Project on AI-Based P∙∙∙

Cellbion Joins Hands with Ahn-Gook Pharmaceutical to Jointly∙∙∙

Cellbion Presents Pocuvotide Study Results at ProsTIC 2026∙∙∙

Cellbion Secures 2.3 Billion KRW in Government Funding for K∙∙∙

Kim Kwon, CEO of Cellbion: "Confident in Competing with Nova∙∙∙

Cellbion Initiates Combination Clinical Trial with Merck's K∙∙∙

Government-Selected Future Novel Drugs... Next-Generation Mo∙∙∙

Cellbion: "Targeting Pluvicto's Blind Spots with a Two-Track∙∙∙

Cellbion Signs Agreement with KDDF for 'Pocuvotide' and Keyt∙∙∙

Promising Next-Generation Anticancer Drug... The Rapid Rise ∙∙∙

Bio-Ventures Reshaping the Domestic Novel Drug Landscape... ∙∙∙

Cellbion Announces Phase 2 Clinical Results for Prostate Can∙∙∙

Cellbion reports 35.9% ORR for ‘177Lu-pocuvotide’ in prostat∙∙∙

Bio Companies Set for Clinical Trials, Showing Confidence wi∙∙∙

Cellbion finalizes readiness for integrated R&D and GMP cent∙∙∙

Cellbion to invest KRW 3.02 billion in the expansion and rel∙∙∙

"Competitor 29.8% vs. Pocuvotide 35.9%"… Cellbion Delivers a∙∙∙

Cellbion Presents Phase 2 Results of Pocuvotide at ASCO GU, ∙∙∙